Bristol’s Oncology Strategy: Stay In The Lead On Immunotherapy
Executive Summary
At the recent ASCO meeting, Bristol’s immunotherapies had a very high profile, paving the way for further development of the company’s PD-1/CTLA-4 combination and development of checkpoint inhibitors in new tumor types.
You may also be interested in...
Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers
In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.
Follow The Leader: Bristol Aims To Build On Head Start In Cancer Immunotherapy
The potential for cancer immunotherapy was the clear takeaway from ASCO 2013. With a lead on the competition, a portfolio with a variety of intriguing mechanisms and many combination trials ongoing, Bristol looks to take immuno-oncology development to the next level.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.